{"title":"激动性免疫检查点调节剂可能损害心脏。","authors":"","doi":"10.1038/s44161-025-00654-w","DOIUrl":null,"url":null,"abstract":"The use of cancer immunotherapies is expanding to patients resistant to current therapies, and emerging regulators of immune checkpoints such as agonist antibodies that directly activate immune responses are being studied. Although these therapeutics are promising, this study highlights the potential for cardiac immune-related adverse events.","PeriodicalId":74245,"journal":{"name":"Nature cardiovascular research","volume":"4 7","pages":"799-800"},"PeriodicalIF":10.8000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Agonistic immune checkpoint regulator may harm the heart\",\"authors\":\"\",\"doi\":\"10.1038/s44161-025-00654-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The use of cancer immunotherapies is expanding to patients resistant to current therapies, and emerging regulators of immune checkpoints such as agonist antibodies that directly activate immune responses are being studied. Although these therapeutics are promising, this study highlights the potential for cardiac immune-related adverse events.\",\"PeriodicalId\":74245,\"journal\":{\"name\":\"Nature cardiovascular research\",\"volume\":\"4 7\",\"pages\":\"799-800\"},\"PeriodicalIF\":10.8000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cardiovascular research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s44161-025-00654-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cardiovascular research","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44161-025-00654-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Agonistic immune checkpoint regulator may harm the heart
The use of cancer immunotherapies is expanding to patients resistant to current therapies, and emerging regulators of immune checkpoints such as agonist antibodies that directly activate immune responses are being studied. Although these therapeutics are promising, this study highlights the potential for cardiac immune-related adverse events.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
